BioRestorative Therapies to Present New Data at ISCT 2026 Highlighting Its Ongoing Phase 2 Clinical Trial in Chronic Lumbar Disease and Its BioCosmeceutical Platform
Rhea-AI Summary
BioRestorative Therapies (Nasdaq: BRTX) will present new clinical and preclinical data at ISCT 2026 in Dublin, May 6-9. Presentations on May 6 include Phase 2 safety and blinded efficacy data for intradiscal MSC injections in chronic lumbar disc disease and preclinical exosome proteomics from its BioCosmeceutical platform.
The company will present at 9:15 AM and 7:00 PM on May 6, 2026, covering ongoing Phase 2 results and MSC exosome source-specific proteomics.
Positive
- None.
Negative
- None.
News Market Reaction – BRTX
In the Apr 30 session, BRTX gained 11.60%, reflecting a significant positive market reaction. Argus tracked a peak move of +11.8% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 30 | Phase 2 data update | Positive | -10.9% | Reported blinded Phase 2 data with sustained pain and function improvements. |
| Mar 19 | Conference data preview | Positive | +11.9% | Announced upcoming presentation of positive blinded Phase 2 BRTX-100 data. |
| Feb 10 | Enrollment completion | Positive | -38.9% | Completed enrollment of 99 patients in Phase 2 BRTX-100 cLDD trial. |
| May 13 | Interim ISCT data | Positive | -7.1% | Presented ISCT 2025 data showing strong efficacy trends and no SAEs. |
| Nov 13 | Early Phase 2 results | Positive | -6.1% | Reported promising preliminary Phase 2 BRTX-100 data with notable improvements. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Clinical trial updates have generally been positive in content but often met with negative price reactions, with only one of five past clinical releases producing an upside move.
Over the past year, BRTX has repeatedly highlighted progress in its BRTX-100 chronic lumbar disc disease program. Clinical releases on Nov 13, 2024, May 13, 2025, and Feb 10, 2026 detailed preliminary and expanding Phase 2 data, including completion of 99-patient enrollment. Updates on Mar 19 and Mar 30, 2026 emphasized meaningful pain and function improvements. Despite these positive signals, four of five tagged clinical news days saw negative 24-hour price reactions, framing today’s conference-driven data update within a pattern of sell-the-news behavior.
Key Terms
mesenchymal stem cells medical
intradiscal injections medical
chronic lumbar disc disease medical
exosome medical
proteomics medical
phase 2 clinical trial regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Data demonstrate progress in each of its MSC-derived programs
MELVILLE, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative," "BRTX," or the "Company") (Nasdaq: BRTX), a late-stage clinical regenerative medicine company focused on stem cell-based therapies and products, today announces that it will present new data at the International Society for Cell & Gene Therapy (ISCT) 2026 Annual Meeting, taking place May 6-9 in Dublin, Ireland. The Company will have two presentations at the conference: safety and blinded efficacy data from its fully enrolled, ongoing Phase 2 clinical trial in chronic lumbar disc disease, and preclinical data on its therapeutic and BioCosmeceutical exosome platform.
Details of the presentation include:
Title: “Late-Stage Phase 2 Clinical Safety and Efficacy Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells: Study Update”
Presenter: Francisco Silva, Founder and Chief Scientist, BioRestorative Therapies
Date: Wednesday May 6, 2026
Session Start Time: 09:15 AM
Title: “MSC Exosome Proteomics Reveal Source-Specific Therapeutic Applications”
Presenter: Michael Joyce, Director of Research and Development, BioRestorative Therapies
Date: Wednesday May 6, 2026
Session Start Time: 07:00 PM
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, the Company's two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and it also operates a commercial BioCosmeceutical platform:
Disc/Spine Program (brtxDISC™): BioRestorative's lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The Company has commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The U.S. Food and Drug Administration ("FDA") has granted Investigational New Drug ("IND") clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
Metabolic Program (ThermoStem®): The Company is developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells ("BADSC") to generate brown adipose tissue ("BAT"), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
BioCosmeceuticals: BioRestorative has developed a commercial BioCosmeceutical platform. Current commercial products are formulated and manufactured in the Company's cGMP, ISO-7 certified clean room facility. Each product features a cell-based secretome enriched with exosomes, proteins, growth factors, peptides, and other carefully selected active ingredients. This proprietary biologic portfolio has been thoughtfully engineered to support skin health and longevity while addressing visible signs of aging and enhancing overall cosmetic performance. Moving forward, BioRestorative also intends to explore the potential of expanding its commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof, and the Company undertakes no obligation to update such statements.
CONTACT:
Investors
CORE IR
investors@biorestorative.com
